中国肺癌杂志Issue(2)：69-74,6.DOI:10.3779/j.issn.1009-3419.2015.02.03
ALK阳性非小细胞肺癌患者克唑替尼耐药的机制和治疗措施
Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer after Resistance to Crizotinib
摘要
Abstract
Lung cancer is the common lethal disease with the highest morbidity and mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer. Recently, the advances in the molecular biology have transformed our view of NSCLC from histopathological descriptions to precise molecular and genetic identities that can be resolved to single-cell level. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are the most crucial tumor driver genes in NSCLC. hTeir tyrosine kinase inhibitors (TKIs) can signiifcantly improve survival of these patients, who have these driver genes’ mutation. Unfortunately, drug resistance would inevitably occur atfer almost all of initial targeted therapy. hTe resistance mechanism and corresponding methods on EGFR-TKIs have been reviewed elsewhere and will not be discussed. We will focus on the mechanism of ifrst generation ALK TKI (crizotinib) resistance in patients with ALK positive NSCLC. Likewise, we will also discuss the current therapies for ALK positive NSCLC patients atfer crizotinib resistance.关键词
肺肿瘤/克唑替尼/间变性淋巴瘤激酶/耐药性Key words
Lung neoplasms/Crizotinib/Anaplastic lymphoma kinase/Drug resistance引用本文复制引用
蒋涛,周彩存..ALK阳性非小细胞肺癌患者克唑替尼耐药的机制和治疗措施[J].中国肺癌杂志,2015,(2):69-74,6.
